Mucosal Melanoma Clinical Trials

50 clinical trials for Mucosal Melanoma across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors — RECRUITING · PHASE1
• Neo-adjuvant Immunotherapy in Patients With Localized Melanoma — RECRUITING · PHASE2
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma — RECRUITING · PHASE1
• Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma — RECRUITING · PHASE2
• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma — RECRUITING · PHASE1
• Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) — RECRUITING · PHASE2
• Axitinib and Nivolumab for the Treatment of Mucosal Melanoma — RECRUITING · PHASE2
• Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery — RECRUITING · PHASE2
• A Beta-only IL-2 ImmunoTherapY Study — RECRUITING · PHASE1
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery — TERMINATED · PHASE2
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery — COMPLETED · PHASE3
• Dinaciclib in Treating Patients With Stage IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma — COMPLETED · PHASE1
• The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma — COMPLETED
• Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases — COMPLETED · PHASE1
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma — NOT_YET_RECRUITING · PHASE2
• Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma — NOT_YET_RECRUITING · PHASE2
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 — TERMINATED · PHASE2
• Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor — TERMINATED · PHASE2
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma — COMPLETED · PHASE2
• A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma — COMPLETED · PHASE2
• Molecular Characterization of Primary Mucosal Melanoma — COMPLETED
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma — WITHDRAWN · PHASE2
• Neoadjuvant and Adjuvant Checkpoint Blockade — COMPLETED · PHASE2
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab — TERMINATED · PHASE2
• Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists — COMPLETED · PHASE1
• Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 — WITHDRAWN · PHASE2
• Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas — COMPLETED · PHASE1
• Atypical MOLes and Melanoma Early Detection Study (MoleMed) — OTHER · NA
• Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma — OTHER · PHASE2
• Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study — OTHER · PHASE2
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma — COMPLETED · PHASE2
• Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM — OTHER · PHASE1
• Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma — NOT_YET_RECRUITING · PHASE2
• Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma — OTHER · PHASE2
• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. — OTHER · PHASE2
• Apatinib Plus SHR1210 in Advanced Mucosal Melanoma — OTHER · PHASE2
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma — WITHDRAWN · PHASE2
• Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma — COMPLETED · PHASE2
• Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era — OTHER · PHASE2
• Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma — COMPLETED · PHASE2
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — COMPLETED · PHASE3
• Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma — COMPLETED · PHASE2
• Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV — TERMINATED · PHASE2

Refine this search